Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment


Incidence of Therapy-Related Myeloid Neoplasia Among Patients with Chronic Lymphocytic Leukemia (CLL) After Fludarabine/Cyclophosphamide (FC) versus Single-Agent Fludarabine (F) as Initial Treatment
Slides from an ASH 2010 presentation and comments from an interview with Bruce D Cheson, MD (12/23/10)

Smith MR et al. Increased incidence of therapy related myeloid neoplasia (t-MN) after initial therapy for CLL with fludarabine-cyclophosphamide (FC) vs fludarabine (F): Long-term follow-up of US Intergroup study E2997. Proc ASH 2010;Abstract 924.

Dr Cheson is Professor of Medicine, Head of Hematology and Director of Hematology Research at Georgetown University Hospital’s Lombardi Comprehensive Cancer Center in Washington, DC.